These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 36651796)
1. Opdualag for metastatic melanoma. Med Lett Drugs Ther; 2023 Jan; 65(1668):e19-e20. PubMed ID: 36651796 [No Abstract] [Full Text] [Related]
2. Lifileucel (Amtagvi): A cellular therapy for melanoma. Med Lett Drugs Ther; 2024 Apr; 66(1701):e77-e78. PubMed ID: 38691651 [No Abstract] [Full Text] [Related]
3. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. Li SN; Wan X; Peng LB; Li YM; Li JH BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848 [TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. Corrie P; Meyer N; Berardi R; Guidoboni M; Schlueter M; Kolovos S; Macabeo B; Trouiller JB; Laramée P Cancer Treat Rev; 2022 Nov; 110():102463. PubMed ID: 36099854 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report]. Di Guardo L Recenti Prog Med; 2022 Jun; 113(6):28e-30e. PubMed ID: 35758129 [TBL] [Abstract][Full Text] [Related]
7. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
8. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
9. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077 [TBL] [Abstract][Full Text] [Related]
12. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Trojaniello C; Festino L; Vanella V; Ascierto PA Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516 [TBL] [Abstract][Full Text] [Related]
13. What impact will BRAF/MEK-inhibitors have on the melanoma treatment armamentarium and are there challenges ahead? Rutkowski P; Rogala P Expert Opin Pharmacother; 2023; 24(10):1101-1103. PubMed ID: 37144819 [No Abstract] [Full Text] [Related]
14. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis. Garzón-Orjuela N; Prieto-Pinto L; Lasalvia P; Herrera D; Castrillón J; González-Bravo D; Castañeda-Cardona C; Rosselli D Dermatol Ther; 2020 Mar; 33(2):e13145. PubMed ID: 31664762 [TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754 [TBL] [Abstract][Full Text] [Related]